newsfilter
← Latest News
Business Wire·

TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call

  • TriSalus Life Sciences (NASDAQ: TLSI) will host a conference call & webcast on Tuesday, November 10, 2026, at 8:30 AM Eastern time to discuss financial results for the quarter ended September 30, 2026.
  • A press release detailing the financial results will be issued prior to the call.
  • Phone participants must register via an online form to receive dial-in details & a PIN via email.
  • The event will be webcast live on the investor relations section of TriSalus' website, with a replay available afterwards.
  • TriSalus is an oncology company integrating its proprietary Pressure-Enabled Drug Delivery (PEDD) technology with standard-of-care therapies & its investigational immunotherapeutic, nelitolimod.
  • The company has three FDA-cleared devices using PEDD technology: the TriNav Infusion System, TriNav Infusion System LV, & the Pancreatic Retrograde Venous Infusion System.
  • Nelitolimod is a class C Toll-like receptor 9 agonist designed to treat the immunosuppressive tumor environment in liver & pancreatic cancers.
  • Patient data from Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials supports the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects.
  • The company is in the final stages of data completion for several phase 1 clinical trials & plans to explore partnership opportunities.
  • David Patience serves as Chief Financial Officer & is the contact for investor & media inquiries.